The role of inflammation in cancer of the esophagus

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 7, 2014, Pages 749-760

  O'Sullivan, Katie E ^a   Phelan, James J ^a   O'Hanlon, Ciara ^a   Lysaght, Joanne ^a   O'Sullivan, Jacintha N ^a   Reynolds, John V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

adenocarcinoma; Barrett's esophagus; esophagus; gastroesophageal reflux disease; inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CURCUMIN; CYCLOOXYGENASE 2; CYTOKINE; HONOKIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; MICRORNA;

ANTINEOPLASTIC ACTIVITY; BARRETT ESOPHAGUS; BILE REFLUX; CANCER GROWTH; CARCINOGENESIS; CHEMOPROPHYLAXIS; COMORBIDITY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; ENERGY METABOLISM; ENZYME INHIBITION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL INFLAMMATION; ESOPHAGUS CANCER; ESOPHAGUS INJURY; GASTROESOPHAGEAL REFLUX; GENOMIC INSTABILITY; HUMAN; IMMUNOMODULATION; INFLAMMATION; METASTASIS; NONHUMAN; OBESITY; PROTEIN FUNCTION; REVIEW; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; WEIGHT REDUCTION; ADENOCARCINOMA; COMPLICATION; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADENOCARCINOMA; ENERGY METABOLISM; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; INFLAMMATION; MICRORNAS; OBESITY;

EID: 84906334685     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.913478     Document Type: Review

References (138)

1. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99(6):860-8
2. Dubecz A, Solymosi N, Stadlhuber RJ, et al. Does the incidence of adenocarcinoma of the esophagus and gastric cardia continue to rise in the twenty-first Century?-a SEER Database Analysis. J Gastrointest Surg 2013. [Epub ahead of print]
3. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100(16):1184-7
4. Edelstein ZR, Farrow DC, Bronner MP, et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007;133(2): 403-11
5. O'Neill JR, Stephens NA, Save V, et al. Defining a positive circumferential resection margin in oesophageal cancer and its implications for adjuvant treatment. Br J Surg 2013;100(8):1055-63
6. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349(23):2241-52
7. Picardo SL, Maher SG, O'Sullivan JN, Reynolds JV. Barrett's to oesophageal cancer sequence: a model of inflammatory-driven upper gastrointestinal cancer. Dig Surg 2012;29(3):251-60
8. Nicholson A, Jankowski J. Acid reflux and oesophageal cancer. Recent Results Cancer Res 2011;185:65-82
9. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124(1):47-56
10. Das D, Chilton AP, Jankowski JA Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 2009;181:161-9
11. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315(26):1650-9
12. Keibel A, Singh V, Sharma MC. Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des 2009;15(17):1949-55
13. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357(9255):539-45
14. Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997;150(5): 1723-34
15. Brigati C, Noonan DM, Albini A, Benelli R Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 2002;19(3): 247-58
16. Burke F, Relf M, Negus R, Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine 1996;8(7):578-85
17. Poehlmann A, Kuester D, Malfertheiner P, et al. Inflammation and Barrett's carcinogenesis. Pathol Res Pract 2012; 208(5):269-80
18. Abdel-Latif MM, Duggan S, Reynolds JV, Kelleher D. Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol 2009; 9(4):396-404
19. Newton M, Bryan R, Burnham WR, Kamm MA Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. Gut 1997;40(1):9-13
20. Freedman J, Lindqvist M, Hellstrom PM, et al. Presence of bile in the oesophagus is associated with less effective oesophageal motility. Digestion 2002;66(1):42-8
21. Hopwood D, Bateson MC, Milne G, Bouchier IA. Effects of bile acids and hydrogen ion on the fine structure of oesophageal epithelium. Gut 1981;22(4): 306-11
22. Nehra D, Howell P, Williams CP, et al. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999;44(5):598-602
23. Nishijima K, Miwa K, Miyashita T, et al. Impact of the biliary diversion procedure on carcinogenesis in Barrett's esophagus surgically induced by duodenoesophageal reflux in rats. Ann Surg 2004;240(1):57-67
24. Dvorak K, Chavarria M, Payne CM, et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to Barrett's esophagus. Clin Cancer Res 2007; 13(18 Pt 1):5305-13
25. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996;98(9):2120-8
26. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-7
27. Garcia JM, Splenser AE, Kramer J, et al. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol 2014;12(2): 229-38.e3
28. Jenkins GJ, Harries K, Doak SH, et al. The bile acid deoxycholic acid [DCA] at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 2004;25(3):317-23
29. Deans DA, Wigmore SJ, Gilmour H, et al. Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 2006;95(11):1568-75
30. Singh S, Sharma AN, Murad MH, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11(11): 1399-412; e7
31. El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005; 100(6):1243-50
32. Anggiansah R, Sweis R, Anggiansah A, et al. The effects of obesity on oesophageal function, acid exposure and the symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2013;37(5):555-63
33. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316(2):129-39
34. Das UN. Is obesity an inflammatory condition? Nutrition 2001;17(11-12): 953-66
35. Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm 2010;2010
36. Snijder MB, van Dam RM, Visser M, Seidell JC. What aspects of body fat are particularly hazardous and how do we measure them? Int J Epidemiol 2006;35(1): 83-92
37. Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res 2002;34(11-12):616-21
38. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4(8):579-91
39. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37(12):1595-607
40. Moller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 1991;325(13):938-48
41. Donohoe CL, Doyle SL, McGarrigle S, et al. Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma. Br J Surg 2012;99(3): 387-96
42. Doyle SL, Donohoe CL, Finn SP, et al. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol 2012; 107(2):196-204
43. Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc 2012;71(1):181-9
44. Aguirre V, Uchida T, Yenush L, et al. The c-Jun NH[2]-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser[307]. J Biol Chem 2000;275(12):9047-54
45. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11(2):183-90
46. Keaney JF Jr, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23(3):434-9
47. Duggan C, Onstad L, Hardikar S, et al. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013;11(8):934-43
48. Howard JM, Beddy P, Ennis D, et al. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg 2010;97(7): 1020-7
49. Howard JM, Pidgeon GP, Reynolds JV. Leptin and gastro-intestinal malignancies. Obes Rev 2010;11(12):863-74
50. Ryan AM, Healy LA, Power DG, et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg 2008; 247(6):909-15
51. Fitzgerald RC, Abdalla S, Onwuegbusi BA, et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002;51(3):316-22
52. Quante M, Bhagat G, Abrams JA, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 2012; 21(1):36-51
53. O'Riordan JM, Abdel-latif MM, Ravi N, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia- adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005;100(6):1257-64
54. Tselepis C, Perry I, Dawson C, et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002;21(39):6071-81
55. Dvorakova K, Payne CM, Ramsey L, et al. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res 2004;10(6): 2020-8
56. Hong S, Lee HJ, Kim SJ, Hahm KB. Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signaling. World J Gastroenterol 2010;16(17):2080-93
57. von Rahden BH, Stein HJ, Feith M, et al. Overexpression of TGF-beta1 in esophageal [Barrett's] adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog 2006;45(10): 786-94
58. Mu Y, Gudey SK, Landstrom M. Non-Smad signaling pathways. Cell Tissue Res 2012;347(1):11-20
59. Onwuegbusi BA, Aitchison A, Chin SF, et al. Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation. Gut 2006;55(6):764-74
60. Buskens CJ, Ristimaki A, Offerhaus GJ, et al. Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma. Scand J Gastroenterol Suppl 2003(239):87-93
61. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118(3): 487-96
62. Mobius C, Stein HJ, Spiess C, et al. COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. Eur J Surg Oncol 2005;31(7):755-9
63. Somja J, Demoulin S, Roncarati P, et al. Dendritic cells in Barrett's esophagus carcinogenesis: an inadequate microenvironment for antitumor immunity? Am J Pathol 2013;182(6):2168-79
64. Harrison RF, Perry I, Jankowski JA. Barrett's mucosa: remodelling by the microenvironment. J Pathol 2000;192(1): 1-3
65. Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, Saarialho-Kere U. Upregulation and differential expression of matrilysin [MMP-7] and metalloelastase [MMP-12] and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001;85(3):383-92
66. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 2002;50(4):451-9
67. Sage H, Decker J, Funk S, Chow M. SPARC: a Ca2+-binding extracellular protein associated with endothelial cell injury and proliferation. J Mol Cell Cardiol 1989;21(Suppl 1)):13-22
68. Grimm M, Lazariotou M, Kircher S, et al. MMP-1 is a [pre-]invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status. J Transl Med 2010;8:99
69. Murray GI, Duncan ME, O'Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185(3):256-61
70. Auvinen MI, Sihvo EI, Ruohtula T, et al. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002;20(13):2971-9
71. O'Sullivan KE, Reynolds JV, O'Hanlon C, et al. Could signal transducer and activator of transcription 3 be a therapeutic target in obesity-related gastrointestinal malignancy? J Gastrointest Cancer 2014;45(1):1-11
72. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9(11): 798-809
73. Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to epithelial cancer-more than a "gut" feeling? Cell Div 2010;5:14
74. Gibson MK, Dhaliwal AS, Clemons NJ, et al. Barrett's esophagus: cancer and molecular biology. Ann N Y Acad Sci 2013;1300:296-314
75. Zhang HY, Zhang Q, Zhang X, et al. Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol 2011;300(3): G454-60
76. Timme S, Ihde S, Fichter CD, et al. STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas. Oncogene 2013. [Epub ahead of print]
77. Jenkins GJ, Mikhail J, Alhamdani A, et al. Immunohistochemical study of nuclear factor-kappaB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers. J Clin Pathol 2007;60(11): 1232-7
78. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000;29(3-4): 222-30
79. Kavanagh ME, O'Sullivan KE, O'Hanlon C, et al. The esophagitis to adenocarcinoma sequence; the role of inflammation. Cancer Lett 2014;345(2):182-9
80. Zhang HY, Hormi-Carver K, Zhang X, et al. In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks. Cancer Res 2009;69(23):9083-9
81. Peters WH, Roelofs HM, Hectors MP, et al. Glutathione and glutathione S-transferases in Barrett's epithelium. Br J Cancer 1993;67(6):1413-17
82. Klebanoff SJ. Myeloperoxidase. Proc Assoc Am Physicians 1999;111(5):383-9
83. Sihvo EI, Salminen JT, Rantanen TK, et al. Oxidative stress has a role in malignant transformation in Barrett's oesophagus. Int J Cancer 2002;102(6):551-5
84. Sundaresan M, Yu ZX, Ferrans VJ, et al. H2O2 for platelet-derived growth factor signal transduction. Science 1995; 270(5234):296-9
85. Bae YS, Kang SW, Seo MS, et al. Epidermal growth factor [EGF]-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 1997;272(1):217-21
86. Fruehauf JP, Meyskens FL Jr. Reactive oxygen species: a breath of life or death? Clin Cancer Res 2007;13(3):789-94
87. Clemons NJ, Shannon NB, Abeyratne LR, et al. Nitric oxide-mediated invasion in Barrett's high-grade dysplasia and adenocarcinoma. Carcinogenesis 2010;31(9): 1669-75
88. Ling FC, Khochfar J, Baldus SE, et al. HIF-1alpha protein expression is associated with the environmental inflammatory reaction in Barrett's metaplasia. Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus/ISDE 2009;22(8):694-9
89. Griffiths EA, Pritchard SA, McGrath SM, et al. Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Br J Cancer 2007;96(9): 1377-83
90. Lai LA, Kostadinov R, Barrett MT, et al. Deletion at fragile sites is a common and early event in Barrett's esophagus. Mol Cancer Res 2010;8(8):1084-94
91. Yang Y, Fruehauf J, Xiang S, Li CJ. Genomic instability in precancerous lesions before inactivation of tumor suppressors p53 and APC in patients. Cell Cycle 2006; 5(13):1443-7
92. O'Sullivan JN, Finley JC, Risques RA, et al. Telomere length assessment in tissue sections by quantitative FISH: image analysis algorithms. Cytometry A 2004; 58(2):120-31
93. Finley JC, Reid BJ, Odze RD, et al. Chromosomal instability in Barrett's esophagus is related to telomere shortening. Cancer Epidemiol Biomarkers Prev 2006; 15(8):1451-7
94. Takubo K, Fujita M, Izumiyama N, et al. Q-FISH analysis of telomere and chromosome instability in the oesophagus with and without squamous cell carcinoma in situ. J Pathol 2010;221(2):201-9
95. Karaman A, Binici DN, Kabalar ME, et al. Genomic instability in patients with Barrett's esophagus. Cancer Genet Cytogenet 2010;201(2):88-93
96. Shimizu T, Marusawa H, Endo Y, Chiba T. Inflammation-mediated genomic instability: roles of activation-induced cytidine deaminase in carcinogenesis. Cancer Sci 2012;103(7):1201-6
97. Morita S, Matsumoto Y, Okuyama S, et al. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma. Carcinogenesis 2011;32(11):1706-12
98. Chong IY, Cunningham D, Barber LJ, et al. The genomic landscape of oesophagogastric junctional adenocarcinoma. J Pathol 2013;231(3):301-10
99. Agrawal N, Jiao Y, Bettegowda C, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012;2(10): 899-905
100. Dulak AM, Schumacher SE, van Lieshout J, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012;72(17): 4383-93
101. Pal J, Bertheau R, Buon L, et al. Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. Oncogene 2011; 30(33):3585-98
102. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5):646-74
103. De Bock K, Georgiadou M, Carmeliet P. Role of endothelial cell metabolism in vessel sprouting. Cell Metab 2013;18(5):634-47
104. Shi LZ, Wang R, Huang G, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med 2011;208(7):1367-76
105. Straus DS. TNFalpha and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol Cancer 2013;12:78
106. Tornatore L, Thotakura AK, Bennett J, et al. The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends Cell Biol 2012; 22(11):557-66
107. Zhang X, Xu L, Shen J, et al. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum. Biochim Biophys Acta 2013;1832(8):1207-16
108. Ando M, Uehara I, Kogure K, et al. Interleukin 6 enhances glycolysis through expression of the glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase-3. J Nippon Med Sch 2010;77(2):97-105
109. Cheung EC, Ludwig RL, Vousden KH. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc Natl Acad Sci USA 2012. 109(50):20491-6
110. Kastelein F, Biermann K, Steyerberg EW, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2013;62(12): 1676-83
111. Angelo LS, Talpaz M, Kurzrock R. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res 2002;62(3):932-40
112. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 2008;10(5):611-18
113. Mauro C, Leow SC, Anso E, et al. NF-kappaB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol 2011;13(10):1272-9
114. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6(11):857-66
115. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302(1):1-12
116. Nguyen GH, Schetter AJ, Chou DB, et al. Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res 2010; 16(23):5824-34
117. Feber A, Xi L, Pennathur A, et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg 2011; 91(5):1523-30
118. Sivarasan N, Smith G. Role of aspirin in chemoprevention of esophageal adenocarcinoma: a meta-analysis. J Dig Dis 2013;14(5):222-30
119. Uotila P. The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol Immunother 1996;43(1):1-9
120. Jankowski J, Barr H. Improving surveillance for Barrett's oesophagus: aspECT and BOSS trials provide an evidence base. BMJ 2006; 332(7556):1512
121. Rees JR, Lao-Sirieix P, Wong A, Fitzgerald RC. Treatment for Barrett's oesophagus. Cochrane Database Syst Rev 2010(1):CD004060
122. Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2013;11(4):382-8
123. Miyashita T, Shah FA, Harmon JW, et al. Do proton pump inhibitors protect against cancer progression in GERD? Surg Today 2013;43(8):831-7
124. Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006;55(11):1538-44
125. Scozzari G, Trapani R, Toppino M, Morino M. Esophagogastric cancer after bariatric surgery: systematic review of the literature. Surg Obes Relat Dis 2013;9(1): 133-42
126. Kastelein F, Spaander MC, Biermann K, et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011;141(6):2000-8; quiz e13-4
127. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008;103(4):825-37
128. Beales IL, Hensley A, Loke Y. Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J Gastrointest Pharmacol Ther 2013; 4(3):69-79
129. Choi SE, Perzan K, Tramontano AC, et al. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. Cancer Prev Res [Phila] 2014;7(3):341-50
130. Alexandre L, Clark AB, Bhutta HY, et al. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis. Gastroenterology 2014;146(3):661-8
131. Prasad G. Modulation of esophageal inflammation in Barrett's esophagus by omega-3 fatty acids, a double-blind placebo controlled randomized pilot study. 2012. [Epub ahead of print]
132. Rao CV, Reddy BS. Modulating effect of amount and types of dietary fat on ornithine decarboxylase, tyrosine protein kinase and prostaglandins production during colon carcinogenesis in male F344 rats. Carcinogenesis 1993;14(7):1327-33
133. Ryan AM, Reynolds JV, Healy L, et al. Enteral nutrition enriched with eicosapentaenoic acid [EPA] preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg 2009; 249(3):355-63
134. Yu C, Zhang Q, Zhang HY, et al. Targeting the intrinsic inflammatory pathway: honokiol exerts proapoptotic effects through STAT3 inhibition in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol 2012;303(5): G561-9
135. Chung MY, Lim TG, Lee KW. Molecular mechanisms of chemopreventive phytochemicals against gastroenterological cancer development. World J Gastroenterol 2013;19(7):984-93
136. Oh TY, Lee JS, Ahn BO, et al. Oxidative stress is more important than acid in the pathogenesis of reflux oesophagitis in rats. Gut 2001;49(3):364-71
137. Jenkins GJ, D'Souza FR, Suzen SH, et al. Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: the potential role of anti-oxidants in Barrett's oesophagus. Carcinogenesis 2007;28(1):136-42
138. Ibiebele TI, Hughes MC, Nagle CM, et al. Dietary antioxidants and risk of Barrett's esophagus and adenocarcinoma of the esophagus in an Australian population. Int J Cancer 2013;133(1):214-24